Q-omics provides the consensus-scored PLEC profile across patient tissues and cancer cell-line models. PLEC expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLEC is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PLEC protein abundance shows 24,543 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where PLEC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEC survival associations across molecular data types. PLEC RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEC RNA expression–survival associations across cancer types. High PLEC expression shows unfavorable associations in MESO, ACC, KIRC, COAD, CESC and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for PLEC RNA expression.
This table summarizes PLEC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLEC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEC shows higher tumor expression in HNSC, KIRC, LIHC, STAD, LUAD and LUSC. The HNSC box plot shows higher PLEC RNA expression in tumor versus normal tissue (log2 FC = +1.757, t-test p < 0.001).
This table shows molecular features associated with PLEC in patient tissues and cancer cell lines. In patient samples, PLEC shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
